Summary.-The effect of methotrexate on solid rodent tumours has been investigated using the spontaneous mammary adenocarcinoma of the female C3H/Bts mouse. As these tumours exhibit a wide range of volume doubling times, calculations of tumour response to methotrexate must be related to doubling time. When methotrexate is injected into the tumour a dose-dependent tumour response is obtained. Systemic citrovorum " rescue " prevents methotrexate lethalities but reduces tumour response by a factor of 2. Methotrexate-treated tumours have an increased volume doubling time post treatment.
THE FOLIC ACID antagonist methotrexate (amethopterin, 4-amino-10-methyl folic acid) has been used clinically in attempts to control a variety of tumours in man. There is, however, very little recorded information as to its effect on solid animal tumours, whether spontaneously occurring or transplanted, and what there is is contradictory. As work in this department was directed at evaluating the efficacy of combining chemotherapy and radiotherapy, using the spontaneous C3H mammary adenocarcinoma as a model, it was necessary to see whether despite conflicting reports in the literature methotrexate would produce detectable effects on this tumour system.
MATERIALS AND METHODS
Animals.-Female mice bearing spontaneous mammary tumours were withdrawn from the C3H/Bts stock colony and caged 8 to a box. They were fed Dixon's CDDM diet with water ad libitum. Tumours had been detected by palpation of the flanks of the mice in the stock colony: the smallest tumour detectable by this routine is about the size of an enlarged inguinal lymph node, 2 mm3. As the supply of tumour-bearing mice runs at about 8-15 per week, experimental groups were made up by allocating new batches of tumour mice randomly betw een the different treatment (Fig. 3a) . Mice dying after an overdose of methotrexate exhibit few external symptoms other than diarrhoea accompanied by weight loss, which is evident from 3 days after intraperitoneal administration. The degree of weight loss 4 days after administration is dose dependent (Fig. 4) than that of the same tumour before injection. In a series of 32 mouse tumours with volume doubling times calculated before and after treatment with 80 mg/kg methotrexate followed by citrovorum rescue the mean pretreatment doubling time was 12-4 4i 2-4 days while the mean post-treatment time was 22*0 ± 2*2 days, a significant difference (0-005 < P < 0.001).
Hi8tological finding8
The pattern of histological damage to be seen in the methotrexate-treated tumours was examined in a small group (24) of tumour-bearing mice which were injected with 80 mg/kg into the tumour and killed serially, 2 mice a day for 12 days. Damage to the intestinal crypt epithelium was clearly demonstrated by the absence of mitotic figures in the crypt cells at 3 and 4 days, and by damage to the villi. Some mitosis starts again at 5 days and by 8 days surviving mice show no intestinal damage. Weight loss is halted 6 days after injection and initial body weight regained 12 days afterwards. These results follow the pattern described for damage and methotrexate injury to the mouse gut by Eder, Rostock and Vogel (1967) but recovery starts one day later here, probably due to the use of intratumour injections.
One day after intratumour injection, injected tumours show no damage apart from localized disruption of tissues around the injected area. After 4 days there are areas of localized haemorrhage and dead cells, and these are still present, although decreasing in size, up to 8-11 days after injection. Although the spleens of mice injected with methotrexate are smaller than those of normal mice, they contain large amounts of haem breakdown products 4, 5 and 6 days after injection.
The metabolic block produced by antifolates can be circumvented by administering citrovorum factor (leucovorin tetrahydrofolate) 24 h after the antifolate. Goldin et al. (1954) showed this in leukaemic DBA male mice after aminopterin injection, and Berenbaum (1964) demonstrated citrovorum rescue in guinea-pigs 214 DE TNTrR A73V RTTr>NWV AT lh TNTR ATTTMOTTR-citrovorum rescue it can be seen that no matter which route of administration is used for the methotrexate the response of the tumour is decreased. Figure 5 shows that when citrovorum " rescue " is carried out 24 h after intraperitoneal methotrexate the tumour response is reduced by a factor of 2-8 at the 40 mg/kg dose level, and 2-2 at the 60 mg/kg level.
Less reduction of tumour response was seen when intratumour injection of methotrexate was followed by citrovorum rescue as the tumour response to methotrexate was reduced by a factor of 2-1 at 60 mg/kg and 1P9 at 80 mg/kg (Fig. 5) (Skipper and Schmidt, 1962) or spontaneous mouse adenocarcinoma (Hirschberg, 1963 Goldin (1966) and Stolfi, Martin and Fugmann (1971) .
Early experiments by Scholler, Phillips and Bittner (1955) using not a true spontaneous tumour but a first generation transplant, produced equivocal effects on inhibition of tumour growth with no increased survival with daily doses of 4-8 mg/kg. The technique used for methotrexate administration in the experiments described here consisted of injecting one large single dose of methotrexate into the tumour, followed 24 h afterwards by citrovorum rescue. There is a considerable amount of both clinical (Sullivan, 1962) and experimental (Delmonte and Jukes, 1962) evidence that shows that fractionated administration of methotrexate results in greater toxicity than does administration of the same dose singly. The increased toxicity of daily doses in the experiment reported by Scholler et al. (1955) may have masked any chemotherapeutic effect on the tumour. The wide range of doubling times of the spontaneous mouse mammary adenocarcinoma makes it essential that all calculations of the response of this tumour to drugs based on changes in volume should utilize the inherent doubling time of the tumour in the calculation. Mean times for tumour recession, or growth retardation, are too insensitive to be satisfactory endpoints. The route of administration is also important. In the experiments described here better results were obtained when methotrexate was injected directly into the tumour, and the subsequent rescuing citrovorum injection was made subcutaneously, than when methotrexate was given intraperitoneally. Using these methods, a small but significant response to methotrexate may readily be demonstrated.
